title: Combination chemotherapy for acute lymphoblastic leukaemia in adults.
abstract: Fifty-one adults with acute lymphoblastic leukaemia were entered into a trial of intense initial chemotherapy and early "prophylaxis" of the central nervous system (CNS). Initial treatment with OPAL (Oncovin (vincristine), prednisolone, adriamycin (doxorubicin), and L-asparaginase (colaspase)) followed by craniospinal or cranial irradiation and intrathecal methotrexate produced remission in 36 patients (71%). Seventeen of these patients relapsed three to 18 months after the start of remission; the remainder had been in remission for 12 to 52 months by the end of the study. The predicted median duration of complete remission was 18.5 months. None of the four patients who initially had clinical evidence of CNS disease, three of whom also had leukaemic cells identical to those found in Burkitt's lymphoma, achieved remission. Those patients who initially had hepatomegaly or splenomegaly had a shorter remission than those without. The predicted median survival was 27 months in those who achieved complete remission, one month in those who did not, and 21 months overall. The addition of colaspase and doxorubicin to vincristine and prednisolone and the use of early CNS treatment clearly improved the remission rate among adults with acute lymphoblastic leukaemia, though the presence and length of remission was affected by the extent of disease at presentation. Burkitt-like leukaemia, which had a poor prognosis, is probably a separate disease and may benefit from a different therapeutic approach.
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001215:Asparaginase / Q000009:adverse effects / Q000627:therapeutic use; D002493:Central Nervous System Diseases / Q000532:radiotherapy; D004317:Doxorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D012075:Remission, Spontaneous; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D014750:Vincristine; D004317:Doxorubicin; D011239:Prednisolone; D001215:Asparaginase; D008727:Methotrexate
references.citation: Biometrika. 1965 Jun;52:203-23
references.pmid: 14341275
references.citation: Cancer. 1976 Aug;38(2):672-7
references.pmid: 1067890
references.citation: Lancet. 1967 Aug 19;2(7512):380-2
references.pmid: 4166329
references.citation: Blood. 1975 Feb;45(2):183-8
references.pmid: 47248
references.citation: Cancer. 1973 Jul;32(1):69-75
references.pmid: 4515259
references.citation: Cancer. 1974 Aug;34(2):418-26
references.pmid: 4527793
references.citation: Presse Med. 1966 May 14;74(24):1241-5
references.pmid: 5936080
references.citation: Cancer. 1971 Jun;27(6):1332-6
references.pmid: 5282619
references.citation: Cancer. 1976 Jun;37(6):2729-35
references.pmid: 1065467
references.citation: Cancer. 1976 Mar;37(3):1256-64
references.pmid: 1063050
references.citation: Oncology. 1975;32(5-6):214-20
references.pmid: 1064827
references.citation: Blood. 1975 Dec;46(6):823-34
references.pmid: 1060469
references.citation: Br Med J. 1975 Dec 13;4(5997):614-7
references.pmid: 1060502
references.citation: Cancer. 1974 Aug;34(2):472-9
references.pmid: 4527847